Next Phase Newsletter

By Tom Crosby, Marketing Manager, LSN

On Monday of this week, Life Science Nation played host to its first conference, Redefining Early Stage Investments, in Boston’s State Room. Over 300 life science industry CEOs, investors and service providers joined together 33 floors above the city for an event that far exceeded anyone’s initial expectations of it – including our own.

LSN set out to organize this with a single idea – the world of private life science investment has changed, but the industry was still navigating via an old roadmap. The countless investor conferences LSN staff had attended were more akin to a memorial to the venture capital days of yore than anything else, and no one was talking about the new categories of investors rapidly entering the space. The RESI concept was to create a forum of entrepreneurs and active early stage investors discussing the marketplace and starting a dialogue that would hopefully lead to some allocations.

Fast forward five months – Over 300 attendees, discussing the hottest investment trends, emerging technologies, and walking away with the beginnings of new partnerships. The impressions that came out of the partnering meetings were overwhelmingly positive. One investor remarked that he had never been to a partnering event where “everyone had such a clear fundraising agenda.” An attending CEO said of RESI that he “couldn’t emphasize how interesting the networking was. The conference was free of many later stage companies that really inhabit a very different universe.” Much to LSN’s satisfaction, these reactions are indicative of the vast majority of feedback received so far.

As a first attempt, the RESI Conference can be said to be a great success. However, there is always room for improvement, and in the coming weeks, LSN will continue to field impressions from our first event as we prepare for the next. We have learned some valuable lessons already, and are taking them fully into account. LSN plans to monitor the attendees of the conference closely in the coming months, so stay tuned as we report out on success stories.

One attendee reflected to me a simple idea that summarized the goal for this event: “[The RESI Conference] fills a gap in the market.” As a company – and as an conference – LSN and the RESI Conference will continue to do its best to fill gaps in the market, create disruptive events, and ultimately, be an advocate for early stage companies seeking to move science forward. Finally, a special thanks to everyone that made this groundbreaking event possible – we look forward to seeing you all again soon!

Tags: biotech, biotechnology, CMO, consulting, CRO, family offices, Fundraising, investor, Investors, issue, letter, life, Life Science, life science nation, medicine, nation, news, newsletter, pharma, Pharmaceutical, private equity, research & development, science, startup, venture capital

By Max Klietmann, VP of Marketing, LSN

The European early stage biotech sector has suffered from a dearth of capital in recent years. This is largely due to a combination of economic uncertainty and a lack of European-based investors targeting riskier early stage opportunities. However, as the biotech sector continues to be a top performer in public markets, with heavy IPO and M&A activity, US investors are increasingly setting their sights on European opportunities.

According to LSN research, private biotechs raised slightly over $1 billion in direct investment through the second quarter of 2012. This is almost a 200% increase relative to the preceeding three months. European biotechs account for close to 45% of this capital. As interest from emerging investor categories outside of the VC realm begin to investigate opportunities in Europe, this trend is likely to accelerate and give many leading clusters in the United States strong competition in terms of advancing innovation to market.

So what are the implications? First and foremost, it signals investor competition for pre-market assets. This is good for the industry at large, because it means that private capital is coming back into the space after an extended dry period, giving many “valley of death” assets some more hope. Secondly, it signals a rebound for the European biotech sector. This means jobs and value-creation, but also signals a wealth of new opportunities for CROs and service providers seeking to expand their client base. Finally, it means more competition among products, and better patient outcomes on a global basis.

Tags: biotech, biotechnology, CMO, consulting, CRO, family offices, Fundraising, investor, Investors, issue, letter, life, Life Science, life science nation, medicine, nation, news, newsletter, pharma, Pharmaceutical, private equity, research & development, science, startup, venture capital

By Lucy Parkinson, Research Analyst

It’s been three months since the decision came down on Association for Molecular Pathology v Myriad Genetics, the Supreme Court case that determined that naturally occurring genes cannot be patented. As one could have predicted, this subject was heavily discussed among investor panels and company presentations. The ruling reflects a paradigm shift, and from watching biotech presentations at the Redefining Early Stage Investments Conference, it was evident that the result of this case has had a significant effect on the business plans of companies, especially in the genomics space.

The decision has produced winners and losers. Myriad Genetics, the main player in the supreme court case can look forward to much more competition; formerly, the company had a 75% monopoly on tests for genes that predispose women to ovarian and breast cancer. (1) Since the decision came down, Myriad’s shares have fallen from $32.50 to $25.23 today. (2) Among other companies, there are fewer clean-cut winners and losers, but there was some consensus among both investors and company CEOs on what the implications were for the industry. Here are a few of the primary points we heard about at RESI:

There has been an “IP re-shuffle.” Cash has been sunk on IP protection or on licensing DNA owned by others. These are asset investments that are now rendered valueless. This has important points of impact – mainly, established players in the market have lost their competitive advantage to more nimble emerging players (who are now attractive investment targets).

Secondly, this IP is no longer an expense for many companies that licensed gene IP in the past, meaning a massive improvement in cost-efficiency. This also means that companies can’t simply rest after patenting genetic IP, they need to maintain a competitive value position, which means more innovation and better drugs coming to market. At RESI CEOs were generally excited about the ruling, and investors were excited about the wealth of new opportunities that are now attractive propositions.

Strong product lines are reaping rewards. This is so often the case in life science; a solid pipeline wins out over one good asset. The Supreme Court’s decision means that companies have to do more than own a DNA IP asset.  The real value has migrated to innovative genomics technologies, and the pitch has changed accordingly. Rather than offering sole access to a gene test, companies now aim to offer faster, more accurate tests than their competitors. In presentations at RESI, speakers stressed the value of assets they’ve developed that are covered by IP protection, such as the sequencing algorithms that read RNA; those assets put these companies in a better position than competitors whose future revenues had relied on the IP value of DNA.

Some companies now have a better product. Companies that offer genetic tests can now broaden their product lines without having to worry about licensing individual genes, and this opportunity to build value should be a significant attraction for investors.

And going forward, the biggest winners will be patients, who can look forward to cheaper, better diagnostics unhindered by litigious DNA IP holders.

There is no doubt that this ruling will have a resounding industry impact and cause a profound shift in how investors view this area. Lower cost entrants into the marketplace are poised to garner significantly more interest from investors, but only if they have a sound strategy for maintaining a market position. Brace for impact!

1. Fidler, Ben. “RainDance Secures $20M, and a Believer in Myriad Genetics.” Xconomy RSS. Xconomy, 29 Apr. 2013. Web. 20 Sept. 2013.

2. http://www.marketwatch.com/investing/stock/mygn

Tags: biotech, biotechnology, CMO, consulting, CRO, family offices, Fundraising, investor, Investors, issue, letter, life, Life Science, life science nation, medicine, nation, news, newsletter, pharma, Pharmaceutical, private equity, research & development, science, startup, venture capital

By Max Klietmann, VP of Marketing, LSN

September marks the beginning of the life science industry conference season. Conferences can be a phenomenal way to generate customer leads, source investor prospects, and discover strategic partners. However, oftentimes these events are heavily underutilized from a marketer’s perspective, minimizing the potential value of participating.  This article is intended to serve as a primer, highlighting some strategies that will increase the value to be drawn from the conference and make these events worth your while.

Do your homework – It is never wise to go in blind – Weeks in advance, you should invest some time and energy in finding out exactly who is going to be attending the event and identifying your top targets. This will help you navigate networking sessions more effectively, and will help you cut through the noise.

Begin your networking before the conference – A well-executed outbound marketing campaign in the weeks leading up to the event will allow you to start a dialogue and “come in warm.” Follow up with your hottest prospects on the phone as well, so that they already know you when you see them at the event. This is especially true for partnering conferences, where your meetings are under time pressure. Having started a dialogue beforehand allows the meeting to start with “As we discussed last time…” rather than “Hello, allow me to introduce my firm…”

Stay organized – Collect as many business cards as possible and take diligent notes. Things will begin to blur in your mind around meeting 25, but being able to recall that your meeting partner’s kids just started second grade in your follow-up emails and calls will keep you personable and will help to build a relationship quickly. Make sure you have a quality CRM to get this information logged as soon as you are back in the office.

Follow-up – The end of the conference marks the beginning of the most important task – follow-up, follow-up, follow-up. No matter how well you did your legwork or how many meetings you scheduled, it is all for naught unless you invest in diligent follow-up. An excellent dialogue can go cold quickly if it isn’t maintained. The most important question to ask at the end of every conversation is “what’s the next step & how do we get there fastest?”

These guidelines should help you be more productive in your conferences this season, and increase the value-per-dollar of participating in these events. Remember, a one day conference requires three weeks of pre-planning and over a month of follow-up, so plan accordingly. Now get out there!

Tags: biotech, biotechnology, CMO, consulting, CRO, family offices, Fundraising, investor, Investors, issue, letter, life, Life Science, life science nation, medicine, nation, news, newsletter, pharma, Pharmaceutical, private equity, research & development, science, startup, venture capital